Peptide Vaccine for Preventing Recurrence of Ovarian or Endometrial Cancer - (HJF 593-21, HJF 592-21)

Preventing cancer recurrence remains an unmet clinical need. A cancer peptide vaccine technology, available from HJF for licensing, has shown significant clinical efficacy in preventing and reducing the risk of recurrence of ovarian and endometrial cancers.

Applications and Advantages

Significant clinical efficacy demonstrated in human studies
Personalized therapy for patients with all levels of folate binding protein on tumor cells
Fully characterized peptide vaccine
Simple formulation and production
Indications including multiple cancer types

Innovation Description

This technology is directed to using a folate binding peptide (FBP)-related cancer vaccine for preventing the recurrence in endometrial and ovarian cancer patients with a high risk of recurrence. Two short peptides, E39 and E39’ are used as vaccine and booster, respectively. Two completed clinical trials, NCT01580696 (phase I/IIa) and NCT02019524 (phase Ib), have shown that this cancer vaccine is efficacious and safe. They were well tolerated and only mild adverse events were observed. A dose regimen for clinical application of this vaccine has been established and patented in the US and Europe.

One of the advantages of this technology is that as demonstrated by the clinical trial outcome, this cancer vaccine is significantly efficacious even among patients with low levels of FBP expression in tumor cells, thus providing a specific, personalized immunotherapy for preventing ovarian and endometrial cancer recurrence.

FIGURE 1: The overall survival curves for patients with FBP IHC 0 or 1 + treated with less than 1000 µg E39, or patients treated with 1000 µg E39.

Inventors

George Peoples, M.D., FACS

Innovation Status

Two clinical studies (phase Ib and phase Ib/IIa) have demonstrated the efficacy and safety of this cancer vaccine. A clinical dose regimen has been established. Please see: Cancer Med. 2019;8(10):4678-4687.